EM-T3Expert Opinion on Drug Safety2018-01-11第 17 卷第 3 期，235-241

Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study

登录后看摘要和中文要点

英文摘要、AI 生成的中文摘要和三条要点、参考文献和引证文献列表、论文图谱，注册免费。

关键词

ombitasvir/paritaprevir/ritonavir dasabuvir HCV genotype 1b chronic hepatitis C compensated cirrhosis sustained virological response drug-drug interactions adverse events antiviral therapy

登录后可以看完整列表。去登录

5次被引阅读 2

被引数据来自 OpenAlex，含本站以外的引用

Expert Opinion on Drug SafetyInforma UK (Taylor & Francis)

应急管理三类

本站发文: 1,929
总被引: 35,949
ISSN: 1474-0338

进入期刊页 →

引用这篇

CHAMORRO‐DE‐VEGA E, GIMÉNEZ‐MANZORRO Á, RODRIGUEZ-GONZALEZ C-G, et al. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study[J]. Expert Opinion on Drug Safety, 2018, 17(3): 235-241. DOI:10.1080/14740338.2018.1424829.

著录项

学科: 医学临床医学肝病学
类型: 研究论文
期刊: Expert Opinion on Drug Safety
卷期页: 第 17 卷第 3 期，235-241
出版: 2018-01-11
语言: 英语
DOI: 10.1080/14740338.2018.1424829

获取来源2 处

Expert Opinion on Drug Safety出版版
页面
PubMed出版版
页面

来源列表来自 OpenAlex；本站不存全文，链接打开的是对方网站

论文图谱

本篇和它的参考文献、引证文献、相似文献

登录后可以看这篇的论文图谱：谁被它引用、谁引用了它、还有哪些相似的研究。